Published in Ther Adv Neurol Disord on September 01, 2013
Optimizing treatment success in multiple sclerosis. J Neurol (2015) 0.90
Effect of glatiramer acetate three-times weekly on the evolution of new, active multiple sclerosis lesions into T1-hypointense "black holes": a post hoc magnetic resonance imaging analysis. J Neurol (2014) 0.84
Multicontrast MRI Quantification of Focal Inflammation and Degeneration in Multiple Sclerosis. Biomed Res Int (2015) 0.80
Non-Local Means Inpainting of MS Lesions in Longitudinal Image Processing. Front Neurosci (2015) 0.79
The Effect of Three Times a Week Glatiramer Acetate on Cerebral T1 Hypointense Lesions in Relapsing-Remitting Multiple Sclerosis. J Neuroimaging (2015) 0.78
A regional consensus recommendation on brain atrophy as an outcome measure in multiple sclerosis. BMC Neurol (2016) 0.77
The Relationship Between Brain MR Spectroscopy and Disability in Multiple Sclerosis: 20-Year Data from the U.S. Glatiramer Acetate Extension Study. J Neuroimaging (2016) 0.77
g-Ratio weighted imaging of the human spinal cord in vivo. Neuroimage (2016) 0.77
Modeling white matter microstructure. Funct Neurol (2017) 0.75
Detection of Focal Longitudinal Changes in the Brain by Subtraction of MR Images. AJNR Am J Neuroradiol (2017) 0.75
Patch-Based Super-Resolution of MR Spectroscopic Images: Application to Multiple Sclerosis. Front Neurosci (2017) 0.75
Fast magnetic resonance spectroscopic imaging techniques in human brain- applications in multiple sclerosis. J Biomed Sci (2017) 0.75
Graph Theory-Based Brain Connectivity for Automatic Classification of Multiple Sclerosis Clinical Courses. Front Neurosci (2016) 0.75
Hyperpolarized (13)C MR metabolic imaging can detect neuroinflammation in vivo in a multiple sclerosis murine model. Proc Natl Acad Sci U S A (2017) 0.75
Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology (1996) 10.26
Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain (2005) 5.29
Relapses and progression of disability in multiple sclerosis. N Engl J Med (2000) 4.17
Toward accurate diagnosis of white matter pathology using diffusion tensor imaging. Magn Reson Med (2007) 3.40
Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain. Ann Neurol (2004) 3.23
Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types. J Neurosci (1993) 3.07
The clinico-radiological paradox in multiple sclerosis revisited. Curr Opin Neurol (2002) 2.85
Imaging outcomes for neuroprotection and repair in multiple sclerosis trials. Nat Rev Neurol (2009) 2.43
Evolution of the blood-brain barrier in newly forming multiple sclerosis lesions. Ann Neurol (2011) 2.43
Experimental allergic encephalomyelitis and multiple sclerosis: lesion characterization with magnetization transfer imaging. Radiology (1992) 2.41
Evidence of elevated glutamate in multiple sclerosis using magnetic resonance spectroscopy at 3 T. Brain (2005) 2.17
Reversible decreases in N-acetylaspartate after acute brain injury. Magn Reson Med (1995) 1.92
Primary-progressive multiple sclerosis. Lancet Neurol (2007) 1.81
Changes in cerebral perfusion precede plaque formation in multiple sclerosis: a longitudinal perfusion MRI study. Brain (2003) 1.75
Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol (2007) 1.73
Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. Brain (1994) 1.68
Serial magnetization transfer imaging to characterize the early evolution of new MS lesions. Neurology (1998) 1.53
Diffusion MRI in multiple sclerosis. Neurology (2005) 1.49
Magnetization transfer changes in the normal appearing white matter precede the appearance of enhancing lesions in patients with multiple sclerosis. Ann Neurol (1998) 1.44
The pathogenesis of lesions and normal-appearing white matter changes in multiple sclerosis: a serial diffusion MRI study. Brain (2000) 1.41
Murine brain macrophages induced NMDA receptor mediated neurotoxicity in vitro by secreting glutamate. Neurosci Lett (1991) 1.35
Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials. Neurology (2004) 1.34
Current and emerging therapies in multiple sclerosis: a systematic review. Ther Adv Neurol Disord (2012) 1.31
MRI contrast uptake in new lesions in relapsing-remitting MS followed at weekly intervals. Neurology (2003) 1.29
The pathologic substrate of magnetic resonance alterations in multiple sclerosis. Neuroimaging Clin N Am (2008) 1.28
Proton magnetic resonance spectroscopic imaging for metabolic characterization of demyelinating plaques. Ann Neurol (1992) 1.24
Time-series analysis of MRI intensity patterns in multiple sclerosis. Neuroimage (2003) 1.23
Black holes in multiple sclerosis: definition, evolution, and clinical correlations. Acta Neurol Scand (2009) 1.17
Proton magnetic resonance spectroscopy in multiple sclerosis. Neuroimaging Clin N Am (2009) 1.17
Magnetization transfer ratio evolution with demyelination and remyelination in multiple sclerosis lesions. Ann Neurol (2008) 1.16
In vivo evaluation of remyelination in rat brain by magnetization transfer imaging. J Neurol Sci (2000) 1.14
Cognitive dysfunction in patients with mildly disabling relapsing-remitting multiple sclerosis: an exploratory study with diffusion tensor MR imaging. J Neurol Sci (2002) 1.12
Choline is increased in pre-lesional normal appearing white matter in multiple sclerosis. J Neurol (2002) 1.06
Chemical pathology of acute demyelinating lesions and its correlation with disability. Ann Neurol (1995) 1.04
Serial proton magnetic resonance spectroscopic imaging, contrast-enhanced magnetic resonance imaging, and quantitative lesion volumetry in multiple sclerosis. Ann Neurol (1998) 1.04
Combined (1)H and (31)P spectroscopy provides new insights into the pathobiochemistry of brain damage in multiple sclerosis. NMR Biomed (2010) 1.04
Measuring myelin repair and axonal loss with diffusion tensor imaging. AJNR Am J Neuroradiol (2010) 1.03
Weekly diffusion-weighted imaging of normal-appearing white matter in MS. Neurology (2000) 1.03
Natural history of secondary-progressive multiple sclerosis. Mult Scler (2008) 1.02
Reduced diffusion in a subset of acute MS lesions: a serial multiparametric MRI study. AJNR Am J Neuroradiol (2012) 1.02
Serial proton MR spectroscopy of contrast-enhancing multiple sclerosis plaques: absolute metabolic values over 2 years during a clinical pharmacological study. AJNR Am J Neuroradiol (2000) 1.02
Diffusion MR imaging in multiple sclerosis: technical aspects and challenges. AJNR Am J Neuroradiol (2007) 1.01
Proton MR spectroscopy with metabolite-nulling reveals elevated macromolecules in acute multiple sclerosis. Brain (2001) 1.00
MR imaging intensity modeling of damage and repair in multiple sclerosis: relationship of short-term lesion recovery to progression and disability. AJNR Am J Neuroradiol (2007) 0.99
Time-series modeling of multiple sclerosis disease activity: a promising window on disease progression and repair potential? Neurotherapeutics (2007) 0.98
Coefficient D(av) is more sensitive than fractional anisotropy in monitoring progression of irreversible tissue damage in focal nonactive multiple sclerosis lesions. AJNR Am J Neuroradiol (2003) 0.95
Multiple sclerosis: magnetization transfer MR imaging of white matter before lesion appearance on T2-weighted images. Radiology (2000) 0.95
Enhanced magnetic resonance imaging in multiple sclerosis. Mult Scler (2000) 0.93
Serial 1H-MRS in relapsing-remitting multiple sclerosis: effects of interferon-beta therapy on absolute metabolite concentrations. MAGMA (2002) 0.93
Serial diffusion-weighted MR imaging and proton MR spectroscopy of acute large demyelinating brain lesions: case report. AJNR Am J Neuroradiol (2002) 0.91
Ring and nodular multiple sclerosis lesions: a retrospective natural history study. Neurology (2010) 0.91
Guidelines for using quantitative magnetization transfer magnetic resonance imaging for monitoring treatment of multiple sclerosis. J Magn Reson Imaging (2003) 0.90
Long-term study of brain 1H-MRS study in multiple sclerosis: effect of glatiramer acetate therapy on axonal metabolic function and feasibility of long-Term H-MRS monitoring in multiple sclerosis. J Neuroimaging (2008) 0.90
Longitudinal magnetic resonance spectroscopic imaging of primary progressive multiple sclerosis patients treated with glatiramer acetate: multicenter study. Mult Scler (2007) 0.89
Quantitative magnetization transfer imaging of pre-lesional white-matter changes in multiple sclerosis. Mult Scler (2002) 0.86
Non-conventional MRI techniques for measuring neuroprotection, repair and plasticity in multiple sclerosis. Curr Opin Neurol (2008) 0.85
Magnetization transfer MRI in multiple sclerosis. J Neuroimaging (2007) 0.85
Proton MR spectroscopy in multiple sclerosis. Neuroimaging Clin N Am (2000) 0.81
Unfolding the long-term pathophysiological processes following an acute inflammatory demyelinating lesion of multiple sclerosis. Magn Reson Imaging (2010) 0.81
1H-MRS in patients with multiple sclerosis undergoing treatment with interferon beta-1a: results of a preliminary study. J Neurol Neurosurg Psychiatry (1998) 0.80
A long-term study of changes in the volume of brain ventricles and white matter lesions after successful liver transplantation. Transplantation (2010) 1.42
Brain tumor classification by proton MR spectroscopy: comparison of diagnostic accuracy at short and long TE. AJNR Am J Neuroradiol (2004) 1.25
Hepatic encephalopathy is associated with posttransplant cognitive function and brain volume. Liver Transpl (2011) 1.05
Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-establishing disease prognosis and monitoring patients. Nat Rev Neurol (2015) 1.03
1H magnetic resonance in the study of hepatic encephalopathy in humans. Metab Brain Dis (2002) 1.00
Decreased white matter lesion volume and improved cognitive function after liver transplantation. Hepatology (2007) 0.98
Cerebral amyloid angiopathy-related inflammation: imaging findings and clinical outcome. Neuroradiology (2014) 0.96
Proton magnetic resonance spectroscopy ((1)H MRS) of human brain tumours: assessment of differences between tumour types and its applicability in brain tumour categorization. Eur Radiol (2002) 0.95
Adult primitive neuroectodermal tumor: proton MR spectroscopic findings with possible application for differential diagnosis. Radiology (2002) 0.94
Noncirrhotic portal vein thrombosis exhibits neuropsychological and MR changes consistent with minimal hepatic encephalopathy. Hepatology (2006) 0.93
Brain magnetic resonance spectroscopy in episodic hepatic encephalopathy. J Cereb Blood Flow Metab (2012) 0.92
Serial diffusion-weighted MR imaging and proton MR spectroscopy of acute large demyelinating brain lesions: case report. AJNR Am J Neuroradiol (2002) 0.91
Magnetic resonance imaging measurement of brain edema in patients with liver disease: resolution after transplantation. Curr Opin Neurol (2002) 0.90
Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes. Mult Scler (2013) 0.87
T2 hyperintensity along the cortico-spinal tract in cirrhosis relates to functional abnormalities. Hepatology (2003) 0.86
Diffusion tensor imaging supports the cytotoxic origin of brain edema in a rat model of acute liver failure. Gastroenterology (2009) 0.86
3 TESLA MR imaging in adults with focal onset epilepsy. Clin Neurol Neurosurg (2013) 0.83
Neuroimaging in acute liver failure. Neurochem Int (2011) 0.80
1H magnetic resonance spectroscopy in multiple sclerosis and related disorders. Neuroimaging Clin N Am (2013) 0.80
Brain magnetic resonance in experimental acute-on-chronic liver failure. Liver Int (2013) 0.79
Oral glutamine challenge and magnetic resonance spectroscopy in three patients with congenital portosystemic shunts. J Hepatol (2004) 0.77
Idiopathic inflammatory demyelinating diseases of the brainstem. Semin Ultrasound CT MR (2013) 0.77
Cortical lesion counts by double inversion recovery should be part of the MRI monitoring process for all MS patients: commentary. Mult Scler (2014) 0.75
[Progressive multifocal leukoencephalopathy associated to natalizumab: the importance of magnetic resonance imaging in its early diagnosis]. Rev Neurol (2015) 0.75
Reprint of: Neuroimaging in acute liver failure. Neurochem Int (2012) 0.75